169 related articles for article (PubMed ID: 22342288)
1. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells.
Goler-Baron V; Sladkevich I; Assaraf YG
Biochem Pharmacol; 2012 May; 83(10):1340-8. PubMed ID: 22342288
[TBL] [Abstract][Full Text] [Related]
2. Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.
Goler-Baron V; Assaraf YG
PLoS One; 2012; 7(4):e35487. PubMed ID: 22530032
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance.
Goler-Baron V; Assaraf YG
PLoS One; 2011 Jan; 6(1):e16007. PubMed ID: 21283667
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
To KK; Tomlinson B
Br J Pharmacol; 2013 Nov; 170(5):1137-51. PubMed ID: 24032744
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
9. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.
Ifergan I; Scheffer GL; Assaraf YG
Cancer Res; 2005 Dec; 65(23):10952-8. PubMed ID: 16322243
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Fischer B; Frei C; Moura U; Stahel R; Felley-Bosco E
Lung Cancer; 2012 Oct; 78(1):23-9. PubMed ID: 22857894
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H
Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434
[TBL] [Abstract][Full Text] [Related]
13. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
16. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
17. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
19. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.
Huang FF; Zhang L; Wu DS; Yuan XY; Yu YH; Zhao XL; Chen FP; Zeng H
PLoS One; 2014; 9(3):e88298. PubMed ID: 24603487
[TBL] [Abstract][Full Text] [Related]
20. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Porcelli L; Giovannetti E; Assaraf YG; Jansen G; Scheffer GL; Kathman I; Azzariti A; Paradiso A; Peters GJ
Curr Drug Targets; 2014; 15(14):1322-30. PubMed ID: 25479544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
